Normal cerebrospinal fluid suppresses the in vitro development of cytotoxic T cells: Role of the brain microenvironment in CNS immune regulation

Journal of Neuroimmunology

Volumn 88, Issue 1-2, 1998, Pages 77-84

  Gordon, Leslie B ^a   Nolan, Scott C ^b   Ksander, Bruce R ^c   Knopf, Paul M ^b   Harling Berg, Christine J ^b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Brain tumor immunity; Cerebrospinal fluid; Immune privilege; Neuroimmunology; P815 mastocytoma; T lymphocyte; TGF

Indexed keywords

NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MATURATION; CEREBROSPINAL FLUID; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; GRAFT REJECTION; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; MOUSE; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES; BRAIN; CELL AGING; CELL LINE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; FEMALE; IMMUNE SYSTEM; IMMUNOLOGIC MEMORY; MASTOCYTOSIS; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; RATS; SPLEEN; STEM CELLS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032146437     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00077-0     Document Type: Article

References (34)

1. Ahmed, R., Gray, D., 1996. Immunological memory and protective immunity: understanding their relation. Science 272, 54-60.
2. Barker, C.F., Billingham, R.E., 1977. Immunologically privileged sites. Adv. Immunol. 25, 1-54.
3. Brent, L., 1990. Immunologically privileged sites. In: Johansson, B.B., Owman, Ch., Widner, H. (Eds.), Pathophysiology of the Blood-Brain Barrier. Elsevier, Amsterdam, pp. 383-394.
4. Brown, D., Wakefield, L.M., Levinson, A.D., Sporn, M.B., 1990. Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. Growth Factors 3, 35-43.
5. Chodobski, A., Szmydynger-Chodobski, J., Vannordall, M.D., Epstein, M.H., Johanson, C.E., 1994. AT1 receptor subtype mediates the inhibitory effect of central angiotensin II on cerebrospinal fluid formation in the rat. Regul. Pept. 53, 123-129.
6. Cserr, H.F., 1974. Relationship between cerebrospinal fluid and interstitial fluid of brain. Fed. Proc. 33, 2075-2078.
7. Cserr, H.F., Berman, B.J., 1978. Iodide and thiocyanate efflux from brain following injection into rat caudate nucleus. Am. J. Physiol. 235, F331-F337.
8. Cserr, H.F., Knopf, P.M., 1992. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today. 13, 507-512.
9. Cserr, H.F., DePasquale, M., Harling-Berg, C.J., Park, J.T., Knopf, P.M., 1992. Afferent and efferent arms of the humoral immune response to CSF-administered albumins in a rat model with normal blood-brain barrier permeability. J. Neuroimmunol. 41, 195-202.
10. Edvinsson, L., Nielsen, K.C., Owman, C.H., West, K.A., 1971. Alterations in intracranial pressure, blood-brain barrier, and brain edema after sub-chronic implantation of a cannula into the brain of conscious animals. Acta Physiol. Scand. 82, 527-531.
11. Flynn, K., Mullbacher, A., 1996. Memory alloreactive cytotoxic T cells do not require costimulation for activation in vitro. Immunol. Cell Biol. 74, 413-420.
12. Flynn, K., Mullbacher, A., 1997. The generation of memory antigen-specific T cell responses by CD28/CD80 interactions in the absence of antigen. Eur. J. Immunol. 27, 456-462.
13. Gordon, L.B., Nolan, S.C., Cserr, H.F., Knopf, P.M., Harling-Berg, C.J., 1997. Growth of P511 mastocytoma cells in Balb/c mouse brain elicits CTL response without tumor elimination. J. Immunol. 159, 2399-2408.
14. Guerder, S., Carding, S.R., Flavell, R.A., 1995. B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors. J. Immunol. 155, 5167-5174.
15. + T cells isolated from different mouse strains. J. Immunol. 155, 3788-3793.
16. 1. Cancer Res. 52, 1386-1392.
17. Ksander, B.R., Streilein, J.W., 1989a. Immune privilege to MHC-disparate tumor grafts in the anterior chamber of the eye: I. Quantitative analysis of intraocular tumor growth and the corresponding delayed hypersensitivity response. Transplantation 47, 661-667.
18. Ksander, B.R., Streilein, J.W., 1989b. Recovery of activated cytotoxic T cells from minor H incompatible tumor graft rejection sites. J. Immunol. 143, 426-431.
19. Ksander, B.R., Streilein, J.W., 1990. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites. J. Immunol. 145, 2057-2063.
20. Kundig, M., Bachmann, M.F., Ohashi, P.S., Hengartner, H., Zinkernagel, R.M., 1996. On T cell memory: arguments for antigen dependence. Immunol. Rev. 150, 63-90.
21. Marquadt, H., Hunkapillar, M.W., Hood, L.E., Twardzik, D.R., DeLarco, J.E., 1983. Transforming growth factors produced by retrovirus-transformed rodent fibroblasts and human melanoma cells: amino acid sequence homology with epidermal growth factor. Proc. Natl. Acad. Sci. U.S.A. 80, 4684-4688.
22. Matzinger, P., 1994. Tolerance, danger and the extended family. Annu. Rev. Immunol. 12, 991-1045.
23. Mescher, F., 1995. Molecular interactions in the activation of effector and precursor cytotoxic T lymphocytes. Immunol. Rev. 146, 177-210.
24. Mule, J.J., Schwarz, S.L., Roberts, A.B., Sporn, M.B., Rosenberg, S.A., 1988. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxix T cells. Cancer Immunol. Immunother. 26, 95-100.
25. Niederkorn, J., Streilein, J.W., Shadduck, J.A., 1981. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest. Ophthal. Vis. Sci. 20, 355-363.
26. Oldendorf, W.H., Davson, H., 1967. Brain extracellular space and the sink action of cerebrospinal fluid. Trans. Am. Neurol. Assoc. 92, 123-127.
27. Pardoux, C., Asselin-Paturel, C., Chehimi, G., Gay, F., Mami-Cnouaib, F., Chouaib, S., 1997. Functional interaction between TGF-beta and IL-12 in human primary allogeneic cytotoxicity and proliferative response. J. Immunol. 158, 136-143.
28. Ranges, G.E., Figari, I.S., Espevik, T., Palladino, M.A. Jr., 1987. Inhibition of cytotoxix T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J. Exp. Med. 166, 991-998.
29. Streilein, J.W., Taylor, A.W., 1997. Immunologic principles related to the nervous system and the eye: Concerning the existence of a neural-ocular immune system. In: Keane, R.W., Hickey, W.F. (Eds.), Immunology of the Nervous System. Oxford University Press, New York, pp. 99-133.
30. Szentistvanyi, I., Patlak, C.S., Ellis, R.A., Cserr, H.F., 1984. Drainage of interstitial fluid from different regions of rat brain. Am. J. Physiol. 246, F835-F844.
31. Tam, J.P., Marquardt, H., Rosberger, D.F., Wong, T.W., Todaro, G.J., 1984. Synthesis of biologically active rat transforming growth factor I. Nature 309, 376-378.
32. Taylor, A.W., Streilein, J.W., 1996. Inhibition of antigen-stimulated effector T cells by human cerebrospinal fluid. Neuroimmunomod. 3, 112-118.
33. Uyttenhove, C., Van Snick, J., Boon, T., 1980. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815: I. rejection by syngeneic mice. J. Exp. Med. 152 (5), 1175-1183.
34. Wilbanks, G.A., Streilein, J.W., 1992. Fluids from immune privileged sites endow macrophages with the capacity to induce antigen-specific immune deviation via a mechanism involving transforming factor-beta. Eur. J. Immunol. 22, 1031-1036.